ChemSpider 2D Image | CPI-169 | C27H36N4O5S

CPI-169

  • Molecular FormulaC27H36N4O5S
  • Average mass528.664 Da
  • Monoisotopic mass528.240662 Da
  • ChemSpider ID32738725

More details:






Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1-[1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide
1-{1-[1-(ethanesulfonyl)piperidin-4-yl]ethyl}-N-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2-methyl-1H-indole-3-carboxamide
1-{1-[1-(ETHANESULFONYL)PIPERIDIN-4-YL]ETHYL}-N-[(4-METHOXY-6-METHYL-2-OXO-1H-PYRIDIN-3-YL)METHYL]-2-METHYLINDOLE-3-CARBOXAMIDE
1-{1-[1-(Ethylsulfonyl)-4-piperidinyl]ethyl}-N-[(4-methoxy-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-2-methyl-1H-indol-3-carboxamid [German] [ACD/IUPAC Name]
1-{1-[1-(Ethylsulfonyl)-4-piperidinyl]ethyl}-N-[(4-methoxy-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-2-methyl-1H-indole-3-carboxamide [ACD/IUPAC Name]
1-{1-[1-(Éthylsulfonyl)-4-pipéridinyl]éthyl}-N-[(4-méthoxy-6-méthyl-2-oxo-1,2-dihydro-3-pyridinyl)méthyl]-2-méthyl-1H-indole-3-carboxamide [French] [ACD/IUPAC Name]
1450655-76-1 [RN]
1H-Indole-3-carboxamide, N-[(1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl]-1-[1-[1-(ethylsulfonyl)-4-piperidinyl]ethyl]-2-methyl- [ACD/Index Name]
CPI-169
N-[(1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl]-1-[1-[1-(ethylsulfonyl)-4-piperidinyl]ethyl]-2-methyl-1H-indole-3-carboxamide
More...
  • Experimental Physico-chemical Properties
  • Miscellaneous
    • Bio Activity:

      Cell Cycle/DNA Damage MedChem Express HY-15956
      Cell Cycle/DNA Damage; MedChem Express HY-15956
      CPI-169 racemate is the racemate form of CPI-169, which is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with a n EC50 of 70 nM, and triggers cell cycle arrest and apoptosis in a variety of cell lines. MedChem Express http://www.medchemexpress.com/5-TAMRA.html
      CPI-169 racemate is the racemate form of CPI-169, which is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apoptosis in a variety of cell lines. MedChem Express HY-15956
      CPI-169 racemate is the racemate form of CPI-169, which is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apoptosis in a variety of cell lines. ;IC50 value: < 1 nM (catalytic activity of PRC2); 70 nM (Cellular EC50) [1];Target: EZH2 inhibitor;In vitro: CPI-169, a representative compound from that effort, inhibits the catalytic activity of PRC2 with an IC50 of < 1nM, decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apoptosis in a variety of cell lines. Importantly, compound treatment triggers a sequence of downstream functional consequences of EZH2 inhibition whereby apoptosis is not induced before ten days of continuous target engagement [1].;In vivo: Administered subcutaneously at 200 mpk twice daily (BID), CPI-169 is well tolerated in mice with no observed toxic effect or body weight loss. MedChem Express HY-15956
      EZH2 MedChem Express HY-15956

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

Density: 1.3±0.1 g/cm3
Boiling Point:
Vapour Pressure:
Enthalpy of Vaporization:
Flash Point:
Index of Refraction: 1.631
Molar Refractivity: 142.7±0.5 cm3
#H bond acceptors: 9
#H bond donors: 2
#Freely Rotating Bonds: 8
#Rule of 5 Violations: 1
ACD/LogP: 2.67
ACD/LogD (pH 5.5): 2.45
ACD/BCF (pH 5.5): 42.57
ACD/KOC (pH 5.5): 510.18
ACD/LogD (pH 7.4): 2.45
ACD/BCF (pH 7.4): 42.56
ACD/KOC (pH 7.4): 510.05
Polar Surface Area: 118 Å2
Polarizability: 56.6±0.5 10-24cm3
Surface Tension: 48.9±7.0 dyne/cm
Molar Volume: 400.6±7.0 cm3

Click to predict properties on the Chemicalize site






Advertisement